Evotec AG (EVTC) Achieves Milestone In Cardioxyl Collaboration
More News related to EVTC
- Evotec and Vifor Pharma Sign Major Cooperation Agreement
- Evotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington's Disease
- Last Day to Vote for the Best IR Program and Best IR Officer
- Last Days to Vote for Companies in the 2010 IR Global Rankings
- Evotec Achieves Milestone in Medicinal Chemistry Collaboration With Ono Pharmaceutical Co., Ltd.
More News related to FDA
- Micromet (MITI) Outlines Clinical Plans for Blinatumomab in ALL
- Celsion Corp. (CLSN) Recommended to Continue Enrollments for ThermoDox Phase III
- Isis Pharmaceuticals (ISIS) Falls On Safety Concerns
- AVANIR Pharma (AVNR) Gets New Patent for PBA Treatment Zenvia
- Curis (CRIS) Announces Publication of CUDC-101 Data
Evotec AG (Nasdaq: EVTC) achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that has successfully moved into clinical testing. This milestone has triggered a success payment from Cardioxyl Pharmaceuticals to Evotec.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
